While Aurobindo Pharma is recalling the cyanocobalamin injection used to treat vitamin B12 deficiency, Sun Pharma is recalling a drug used to increase tear production in the eyes
While Aurobindo Pharma is recalling the cyanocobalamin injection used to treat vitamin B12 deficiency, Sun Pharma is recalling a drug used to increase tear production in the eyes
Leading pharmaceutical companies Aurobindo Pharma, Sun Pharma and Jubilant are recalling various products in the US market for various reasons, according to the US Food and Drug Administration’s (USFDA) latest enforcement report.
While Aurobindo Pharma is recalling cyanocobalamin injection used to treat and prevent vitamin B12 deficiency, Mumbai-based Sun Pharma is recalling a drug used to increase natural tear production in the eyes.
Similarly, Jubilant Cadista is recalling a drug used to treat various inflammatory conditions.
Jubilant Cadista Pharmaceuticals is a wholly owned subsidiary of Cadista Holdings Inc, which is part of Noida-based Jubilant Life Sciences.
The USFDA said Aurobindo Pharma USA Inc, a unit of the Hyderabad-based drugmaker, is recalling 4,33,809 vials of cyanocobalamin injections because it is a “subpotent drug.”
The New Jersey-based company initiated the recall on April 5.
The US health agency found that US-based Sun Pharmaceutical Industries Inc is recalling 73,030 boxes of Cequa (cyclosporine ophthalmic solution) because it is a “subpotent drug”.
In addition, there were few out-of-spec test results and the presence of particulate matter in the affected lot, the USFDA cited as reasons for the company to initiate the recall.
The company, a subsidiary of Sun Pharma, initiated the recall on April 1 of this year.
The USFDA found that Salisbury-based Jubilant Cadista Pharmaceuticals Inc. is recalling 19,222 bottles of methylprednisolone tablets because they are “subpotent.”
According to the US health agency, New Jersey-based Macleods Pharma USA Inc is also recalling 4,872 bottles of a drug used to treat or prevent osteoporosis that was manufactured in Baddi, Himachal Pradesh because “content specifications are not consistent.” The USFDA classified the recalls as Class III, which is initiated in a “situation where use of or exposure to an infringing product is unlikely to result in any adverse health consequences.”
The US generics market was valued at around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products.
